Tiziana Life Sciences PLC Stock News

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new neuroimaging data which shows its investigational drug intranasal foralumab improved White Matter Z-scores in patients with non-secondary progr

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been approved by the US Food and Drug Administration to expand patient enrollment in its non-active Secondary Progressive Multiple Scleros

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled additional positive results from its Expanded Access Program for patients with non-active secondary progressive multiple sclerosis (na-SPMS). The c

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its study on foralumab, the company's lead candidate, was published in Neurology Today, the esteemed news source of the American Academy of Neurology (AAN)

Tiziana Life Sciences Ltd (NASDAQ:TLSA) unveiled new quantitative PET imaging data on foralumab at the Annual Meeting of the American Academy of Neurology in Denver. The company presented data from it

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will be presenting new data about its lead clinical asset foralumab at the Annual Meeting of the American Academy of Neurology being held from

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that chairman of its Scientific Advisory Board Dr. Howard Weiner will present positive data on intranasal anti-CD3 monoclonal antibody (mAb) in model

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients, which have sh

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies,

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has filed a new patent application relating to the composition and methods for combining a GLP-1 receptor agonist (ra) and foralumab, its lead

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the first patient has been dosed in its Phase 2a study which is comparing two doses of its investigational therapeutic intranasal foralumab and p

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies

Biotechnology firm Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it had successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigh

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies

Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASDAQ:TLSA). Sign-off by the US Food & Drug Administ